{"slug":"italy","tag":"italy","variants":["italy"],"description":"No description yet","count":4,"kinds":{"person":4},"related":[{"slug":"immunotherapy","tag":"immunotherapy","shared":2},{"slug":"cervical","tag":"cervical","shared":1},{"slug":"melanoma","tag":"melanoma","shared":1},{"slug":"neoadjuvant","tag":"neoadjuvant","shared":1},{"slug":"rare-cancers","tag":"rare-cancers","shared":1},{"slug":"sarcoma","tag":"sarcoma","shared":1},{"slug":"urothelial","tag":"urothelial","shared":1}],"records":[{"id":"andrea-necchi","kind":"person","name":"Andrea Necchi","route":"/people/andrea-necchi/","tldr":"Led PURE-01, the first neoadjuvant pembrolizumab trial in bladder cancer, and now leads bladder-preserving immunotherapy studies."},{"id":"domenica-lorusso","kind":"person","name":"Domenica Lorusso","route":"/people/domenica-lorusso/","tldr":"Led KEYNOTE-A18, which showed adding pembrolizumab to chemoradiotherapy improves survival in locally advanced cervical cancer."},{"id":"paolo-ascierto","kind":"person","name":"Paolo A. Ascierto","route":"/people/paolo-ascierto/","tldr":"Italian melanoma oncologist who co-led CheckMate 238, CheckMate 067 and the COLUMBUS BRAF/MEK trial."},{"id":"silvia-stacchiotti","kind":"person","name":"Silvia Stacchiotti","route":"/people/silvia-stacchiotti/","tldr":"Italian oncologist who leads histology-specific trials in ultra-rare sarcomas and the Connective Tissue Oncology Society."}]}